Fred Cohen (Austism)
| This article is a stub. You can help by expanding it. |
Contents
Biographical Information
"Prior to joining TPG Biotech in 2001, Dr. Cohen was a Professor of Medicine and Pharmacology at the University of California, San Francisco. Dr. Cohen has played a role on the Boards or Scientific Advisory Boards of a variety of Biotechnology companies. He currently serves on the boards of Axcan Pharma, CardioDx, Expression Diagnostics (XDx), FivePrime, Genomic Health, Nodality, Quintiles Transnational Corp., Roka Biotechnology, and Veracyte. He received his M.D. from Stanford in 1984, his D.Phil. from Oxford as a Rhodes Scholar in 1980 and his B.S. in 1978 from Yale University. Dr. Cohen was elected to the Institute of Medicine of the National Academics in 2004 and the American Academy of Arts & Sciences in 2008.
"Dr. Cohen and Dr. Geoffrey Duyk are also responsible for the funds’ structured financial investments, SP1 and JCR."[1]
Affiliations
- Trustee, Autistica
